A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells

A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells

While Polo-like kinase 1 (PLK1) inhibitors have shown promise in clinical settings for treating triple-negative breast cancer tumors and other solid tumors, they are limited by their ability to bind non-selectively to the ATP kinase domain. Therefore, we sought to develop a PLK1 allosteric inhibitor...

Full description

Bibliographic Details
Main Authors: Jankiben R. Patel, Prasad Thangavelu, Renee M. Terrell, Bridg’ette Israel, Arindam Basu Sarkar, A. Michael Davidson, Kun Zhang, Rahul Khupse, Syreeta L. Tilghman
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Biomolecules
Subjects:
polo-like kinase 1
triple-negative breast cancer
mammospheres
allosteric inhibitor
Online Access:https://www.mdpi.com/2218-273X/12/4/531

Internet

https://www.mdpi.com/2218-273X/12/4/531

Similar Items